[Qingxue Xiaozhi Formula ameliorates endothelial inflammation in glucose and lipid metabolism disorders via visceral adipose tissue exosome miR-27b-3p-mediated PPARα/NF-κB signaling pathway].
Zhang M., Guo ZX., Zhang L., Zhou MX., Li SN., Liu WH.
Animal Study, published in Zhongguo Zhong Yao Za Zhi (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Zhongguo Zhong Yao Za Zhi (2026)
- Country
- China
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42392816
- DOI
- 10.19540/j.cnki.cjcmm.20251222.801
Abstract (original English)
This study aimed to explore the mechanism of Qingxue Xiaozhi Formula in ameliorating endothelial inflammation in glucose and lipid metabolism disorders through the visceral adipose tissue exosome miR-27b-3p-mediated peroxisome proliferator-activated receptor α(PPARα)/nuclear factor-kappa B(NF-κB) signaling pathway. A Zucker diabetic fatty(ZDF) rat model was induced by Purina 5008 feed, and inflammation models of adipocytes and human umbilical vein endothelial cells(HUVECs) were induced by glucose combined with oxidized low-density lipoprotein(ox-LDL). ZDF rats were randomly allocated into model, low-dose Qingxue Xiaozhi Formula, high-dose Qingxue Xiaozhi Formula, and metformin groups, with Zucker lean(ZL) rats serving as the normal group. After 7 weeks of drug intervention, the body weight, Lee's index, fasting blood glucose, oral glucose tolerance, serum lipid levels, and liver enzyme levels were measured. Hepatic pathological changes were observed via hematoxylin-eosin(HE) and oil red O staining. miRNAs sequencing was used to quantify the expression of miRNAs in exosomes derived from the visceral adipose tissue. Immunofluorescence staining was employed to detect aortic vascular cell adhesion molecule-1(VCAM-1) expression. The cell counting kit-8(CCK-8) method was adopted to examine cell viability. qRT-PCR, enzyme-linked immunosorbent assay(ELISA), and Western blot were employ
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.